Sort
48,018 grants matching “immunotherapy”
Pre-clinical testing of a novel immunotherapy [recombinant T cell receptor ligand
$474,779Jennifer M Loftis · Oregon Health & Science University · RC1 · FY2009 · DA
Vaccines for the Treatment of Opiate Addiction
$474,750Kim D Janda · Scripps Research Institute, The · R01 · FY2010 · DA
Strategies to Enhance Lymphoid Recovery After Radiation-Induced Injury
$474,750Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2009 · AI
Strategies to Enhance Lymphoid Recovery After Radiation-Induced Injury
$474,750Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2008 · AI
Immunological Priming to Hepatitis B Virus
$474,750Masanori Isogawa · Scripps Research Institute, The · R01 · FY2009 · AI
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$474,721Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$474,721Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Admin Core
$474,713Michael Barry Kastan · Duke University · P30 · FY2025 · CA
Mitochondrial R-loop in sepsis-induced cardiomyopathy
$474,668Wei Huang · University Of Cincinnati · R01 · FY2025 · HL
Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy
$474,656Duane A. Mitchell · University Of Florida · R01 · FY2024 · CA
Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy
$474,656Duane A. Mitchell · University Of Florida · R01 · FY2025 · CA
Hydrogel-Based Cytokine Carrier for Oral cancer Therapy
$474,640New York University · R01 · FY2005 · DE
Role of the DR/DQ super enhancer in MHC-II expression
$474,632Jeremy M. Boss · Emory University · R01 · FY2020 · AI
Targeting Metabolic Vulnerabilities of Triple Negative Breast Cancer Stem Cells
$474,547Max S. Wicha · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Targeting Metabolic Vulnerabilities of Triple Negative Breast Cancer Stem Cells
$474,547Max S. Wicha · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Aerosolized microbots as a platform for targeted lung therapy
$474,497David Wm Marr · Colorado School Of Mines · R01 · FY2025 · EB
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway
$474,416Wafik S El-Deiry · Brown University · R01 · FY2023 · CA
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway
$474,416Wafik S El-Deiry · Brown University · R01 · FY2022 · CA
Targeting lymph node metastases to block cancer progression
$474,295Timothy P Padera · Massachusetts General Hospital · R01 · FY2024 · CA
Modulation of Tumor Microenvironment by Microbiome in Head and Neck Cancer
$474,275Shi-Long Lu · University Of Colorado Denver · R56 · FY2019 · DE
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
$474,236Alexander H. Stegh · Washington University · R01 · FY2024 · NS
Resource for Nonhuman Primate Immune Reagents
$474,190Francois J Villinger · Emory University · R24 · FY2013 · OD
How RNA binding proteins control effector T cell responses
$474,189Anthony T. Vella · University Of Connecticut Sch Of Med/Dnt · R01 · FY2024 · CA
Neoadjuvant immunotherapy approaches to early stage melanoma
$474,126Meenhard Herlyn · Wistar Institute · P50 · FY2025 · CA
Therapeutically harnessing anti-viral resident memory T cells in solid tumors
$474,122Pamela Rosato · Dartmouth College · R01 · FY2024 · CA